Autor: |
Kato K; Department of Neuropsychiatry, Yamagata University School of Medicine, Yamagata, Japan., Yasui-Furukori N, Fukasawa T, Aoshima T, Suzuki A, Kanno M, Otani K |
Jazyk: |
angličtina |
Zdroj: |
Therapeutic drug monitoring [Ther Drug Monit] 2003 Aug; Vol. 25 (4), pp. 473-7. |
DOI: |
10.1097/00007691-200308000-00010 |
Abstrakt: |
The effects of itraconazole, a potent inhibitor of cytochrome P450 (CYP) 3A4, on the plasma kinetics of quazepam and its two active metabolites after a single oral dose of the drug were studied. Ten healthy male volunteers received itraconazole 100 mg/d or placebo for 14 days in a double-blind randomized crossover manner, and on the fourth day of the treatment they received a single oral 20-mg dose of quazepam. Blood samplings and evaluation of psychomotor function by the Digit Symbol Substitution Test and Stanford Sleepiness Scale were conducted up to 240 h after quazepam dosing. Itraconazole treatment did not change the plasma kinetics of quazepam but significantly decreased the peak plasma concentration and area under the plasma concentration-time curve of 2-oxoquazepam and N-desalkyl-2-oxoquazepam. Itraconazole treatment did not affect either of the psychomotor function parameters. The present study thus suggests that CYP 3A4 is partly involved in the metabolism of quazepam. |
Databáze: |
MEDLINE |
Externí odkaz: |
|